CurrentEmblemHealthPolicy N/A

Oral HIV Pre-Exposure Prophylaxis (PrEP)

Defines coverage, FDA-approved oral PrEP options, cost tiers, zero-dollar copay criteria, target populations, and safety considerations for HIV-negative individuals at risk of HIV exposure.

Policy Summary

PayerEmblemHealth

PolicyOral HIV Pre-Exposure Prophylaxis (PrEP)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionPrescriber must document that the patient is HIV-negative and at risk for HIV exposure; address adherence barriers before initiating PrEP.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 99%prevent sexual HIV acquisition

≥74%prevent HIV from injection drug use

2FDA-approved oral PrEP products

eligiblezero-dollar copay possible

Coverage and Clinical Eligibility

Coverage and Copay Eligibility

Covered when ALL of the following are met:

PrEP initiation criteria: Therapy is being prescribed for PrEP; the patient is HIV-negative and assessed by the prescriber to be at high risk for HIV infection

Prescriber assessment and documentation required; see provider actions for documentation guidance

Population considerations by product: Product-specific population notes: Truvada (TDF/FTC) was studied in cisgender men and women, transgender men and women, and people who inject drugs; Descovy (TAF/FTC) was studied in cisgender men who have sex with men and transgender women and is NOT approved for individuals at risk from receptive vaginal sex

Use product population/studies to guide appropriate prescribing

Zero-dollar copay additional criteria: To qualify for a zero-dollar copay when applicable, the patient must not be at risk for HIV-1 infection from receptive vaginal sex OR have a contraindication to or be unable to take generic emtricitabine/tenofovir disoproxil fumarate (TDF/FTC)

Policy Summary

PayerEmblemHealth

PolicyOral HIV Pre-Exposure Prophylaxis (PrEP)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionPrescriber must document that the patient is HIV-negative and at risk for HIV exposure; address adherence barriers before initiating PrEP.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Prescriber Responsibilities and Administrative Rules

Prior Authorization

Prior authorization / cost-sharing

No explicit prior authorization requirements are stated for PrEP coverage. Coverage and any zero-dollar copay eligibility are contingent on meeting the listed criteria for PrEP and high-risk status; there are no specific denial triggers detailed beyond failure to meet those criteria.

Coverage contingent on meeting PrEP criteria and high-risk status
No explicit prior authorization required

Step Therapy

Step therapy

There are no step therapy requirements specified for initiation of PrEP in the source policy.

Documentation Required

Documentation requirement

Prescriber must document that the patient is HIV-negative and at risk for HIV exposure. For patients new to PrEP, consider addressing potential adherence barriers prior to initiation. Documentation should support high-risk status per the prescriber's assessment.

Document patient HIV-negative status
Document that patient is at high risk for HIV exposure per prescriber
Address adherence barriers prior to initiation when possible

Denial Risk

Denial risk / contingencies

No explicit denial triggers are listed in the source. However, coverage and zero-dollar copay eligibility are contingent on meeting the specified criteria for PrEP use and high-risk designation; failure to meet those criteria may result in denial of zero-dollar copay or different cost-sharing.

No explicit denial triggers stated
Denial/coverage contingencies tied to meeting PrEP criteria and high-risk status

Clinical Background

Oral pre-exposure prophylaxis (PrEP) is indicated for HIV-negative individuals at risk for HIV exposure and is administered as daily oral therapy (with an intermittent PrEP 2-1-1 dosing option noted for some regimens). FDA-approved oral products named in this policy are Descovy (TAF/FTC) and Truvada (TDF/FTC). Clinical evidence summarized in the policy supports high effectiveness of oral PrEP for preventing sexual HIV acquisition (up to 99%) and substantial effectiveness for preventing HIV acquisition related to injection drug use (≥74%). Providers should assess HIV-negative status and HIV exposure risk before initiating PrEP and select the product consistent with approved populations and safety considerations.

OpenPayer

Oral HIV Pre-Exposure Prophylaxis (PrEP)

Coverage and Clinical Eligibility

Prescriber Responsibilities and Administrative Rules

Clinical Background

Key Definitions